News & Trends - Pharmaceuticals
AbbVie’s phase 3 wins for Humira successor Skyrizi
Pharma News: AbbVie is in a race against time as patent expiry of its Humira inflammatory diseases blockbuster draws near in 2023.
The company’s follow-up drug Skyrizi (risankizumab) is important to AbbVie’s strategy to negotiate the $20 billion patent cliff from Humira, which has already seen sales decline outside of the US where it has already lost protection against less expensive competitors.
In AbbVie’s latest announcements, Skyrizi demonstrated significant improvements in clinical remission and endoscopic response in two Phase 3 Crohn’s Disease induction studies, ADVANCE and MOTIVATE. The ADVANCE study enrolled patients who had an inadequate response or were intolerant to conventional and/or biologic therapy. The MOTIVATE study evaluated patients who had responded inadequately or were intolerant to biologic therapy.
Additionally, Skyrizi’s Phase 3 study results from the KEEPsAKE-1 and KEEPsAKE-2 clinical trials demonstrated improvements in disease activity across joint and skin symptoms among psoriatic arthritis patients paving the way for a launch in additional indications.
With Skyrizi, AbbVie hopes to cover many of the indications where Humira has become standard therapy.
At the 39th Annual JP Morgan Healthcare Conference on 12 January 2021, AbbVie CEO Richard Gonzalez indicated that the company expects global sales of more than $7B for Skyrizi by 2025.
You may also like Changing MSL value proposition accelerated by the COVID-19 pandemic
News & Trends - MedTech & Diagnostics
Stryker partners with local researchers to advance shoulder joint surgery
MedTech & Diagnostics News: Joint replacement is a commonly performed major surgical procedure that has considerable success in alleviating pain […]
MoreNews & Trends - Pharmaceuticals
Over two-thirds of Aussies missing healthcare appointments
Pharma News: Over 70% of Australians have postponed or cancelled healthcare appointments in the last 12 months. The primary reason […]
MoreNews & Trends - Pharmaceuticals
Opposition decries incremental change as New Zealand government defends Pharmac budget
Pharma News: New Zealand’s Associate Health Minister has made headlines by unveiling Pharmac’s largest ever budget of $6.294 billion over […]
MoreMedical
Telehealth’s 10-year leap in 10 days: Reshaping hospital EDs
Medical: As overcrowding and ramping continue to challenge emergency departments across Australia, the concept of virtual emergency departments (EDs) emerges […]
More